Home Blog Page 508

Shoplazza Adopts Agentic Commerce Architecture to Power AI-Driven E-commerce Operations

TORONTO, March 17, 2026 /PRNewswire/ — Shoplazza, a global commerce platform serving direct-to-consumer (DTC) brands, today announced the adoption of an Agentic Commerce architecture across its platform, introducing AI agents that can directly execute operational tasks within e-commerce workflows.

Agentic commerce shifts e-commerce from tool-based management to goal-based execution. Instead of navigating multiple dashboards or configuring workflows step by step, merchants can simply describe the business outcome they want, and the platform coordinates the necessary actions across storefront operations, payments, marketing tools, and customer management systems. The platform can automatically execute tasks such as creating campaigns targeting specific customers, updating storefront merchandising, launching campaigns, and monitoring performance.

At the core of this capability is Shoplazza’s proprietary Ecom Agent orchestration layer, which coordinates how AI agents interact with the platform’s commerce systems. This infrastructure allows agents to securely access different parts of the platform and execute tasks across storefront management, payments, marketing, and customer data while maintaining merchant-defined permissions and safeguards. The platform also evaluates results using real transaction data, enabling the system to continuously improve how similar tasks are executed over time.

A recent industry report from 36Kr highlights Shoplazza as an example of how commerce platforms are evolving toward Agentic Commerce. The report notes that e-commerce infrastructure is moving beyond traditional SaaS platforms to AI-enabled systems that can automate operational tasks and assist merchants in running day-to-day commerce activities.

“E-commerce is entering its deepest waters. The merchants who survive aren’t looking for more tools; they need an intelligent co-pilot,” said Jeff Li, Founder and CEO of Shoplazza. “That’s why we’re building end-to-end AI agents that don’t just execute tasks, but think, analyze, and optimize across the entire customer journey.”

Founded in 2017, Shoplazza provides global commerce infrastructure that enables businesses to build and operate online stores while coordinating payments, marketing, fulfillment, and customer operations within a unified platform. Today, the platform supports more than 650,000 merchants serving consumers in over 180 countries and regions, and operates within an ecosystem of more than 500 global partners.

About Shoplazza

Shoplazza is a Canadian commerce infrastructure platform that enables global businesses to build, launch, and scale their online stores. Built with an agentic commerce architecture, the platform integrates storefront technology, payments, marketing tools, and operational intelligence to support merchants operating across multiple markets. Learn more at https://www.shoplazza.com/.

 

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027

SUZHOU, China, March 17, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, for the treatment of advanced malignant solid tumors. JSKN027 is the company’s fifth ADC candidate entering clinical development, as well as the world’s first PD-L1/ VEGFR2 bispecific ADC to advance into clinical trials.

As the global burden of malignant tumors continues to rise, there is an urgent clinical need for more effective and innovative therapies applicable across various tumor types. PD-L1 is a key molecule in regulating immune responses, and VEGFR2 is a core signaling hub in tumor angiogenesis. Within the immunosuppressive microenvironment of various solid tumors, the VEGF/VEGFR signaling pathway and the PD-1/PD-L1 axis exhibit a synergistic interplay, collectively driving immune evasion and providing a new strategy for dual-target therapy. JSKN027 is an innovative bispecific ADC designed based on this synergistic mechanism. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody’s Fc region. This design confers multiple mechanisms of action, including targeted chemotherapy, anti-angiogenesis and immunotherapy. It is expected to synergistically enhance antitumor efficacy and overcome therapeutic resistance, offering a promising treatment strategy across solid tumors.

JSKN027-101 is an open-label, multi-center, Phase I clinical study, including dose-escalation and dose-expansion phases. This study aims to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN027 in patients with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

About JSKN027

JSKN027 is a first-in-class bispecific ADC designed to co-engage PD-L1 and VEGFR2. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody’s Fc region – maintaining a strong safety profile while unlocking potent anti-tumor activity.

JSKN027’s efficacy stems from a unique three-fold synergistic mechanism. Beyond the standard ADC effects of targeted cell killing and bystander activity, it also inhibits tumor angiogenesis by blocking VEGF/VEGFR2 signaling and reverses immune suppression by disrupting the PD-1/PD-L1 checkpoint. This integrated attack enhances overall anti-tumor power and is anticipated to help overcome therapeutic resistance. As a result, JSKN027 is poised to offer a novel and robust treatment avenue for patients across multiple solid tumor types. The Phase I clinical study of JSKN027 in patients with advanced malignant solid tumors has been conducted in China.

About Alphamab Oncology

Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.

Mitrade Secures Five Global Industry Awards in 2026 as Asia Traders Reassess Counterparty Risk

KUALA LUMPUR, Malaysia, March 17, 2026 /PRNewswire/ — CFD broker Mitrade announced five awards, positioning the recognition against a backdrop of heightened volatility and monetary divergence across the region.

The US-Iran conflict and Tehran’s leadership transition have pushed oil past $109, rocking global markets. Asian equities face energy and shipping disruptions. A resurgent US dollar has strained the Vietnamese dong and pushed the Indonesian rupiah toward Rp17,000, while regional currencies track widening policy divergence.

For leveraged CFD traders, these conditions often result in shorter positioning cycles and increased margin sensitivity. Rising retail participation has also sharpened focus on broker credibility and overall financial safeguards.

Since 2025, Mitrade has provided aggregate client fund insurance coverage of up to US$1 million for clients onboard under its CIMA and FSC-regulated entities, later extended to include its FSCA-regulated entity. The coverage provides protection for eligible clients in the unlikely event of broker insolvency.

Kevin Lai, Vice President of Mitrade Group, said operational stability and fund safety are central to trading decisions in the region.

“In complex market conditions, traders assess both price direction and the resilience of the institutions they use,” Lai said. “At Mitrade, adherence to client money rules, independent audits and insurance coverage reflect the standards traders increasingly expect when choosing a broker.”

In 2026, Mitrade secured five industry awards:

  • Best Broker MENA 2026 — World Business Outlook
  • Best Multi-Asset Trading 2026 — FX Daily Info
  • Best Broker Education Global 2026 — International Business Magazine
  • Regulated Broker of the Year Global 2026 — International Business Magazine
  • Best CFD Broker Global 2026 — Global Business and Finance Magazine

The company said the recognition reflects its emphasis on trader education and providing market context through structured resources and analysis.

About Mitrade

Mitrade is a globally recognised, award-winning CFD trading platform licensed under the Cayman Islands’ CIMA (SIB1612446), Mauritius’s FSC (GB20025791), Australia’s ASIC (AFSL398528), South Africa’s FSCA (FSP 54842) and Cyprus’s CySEC (CIF438/23). The group democratises market access, connecting 6M+ traders to 900+ OTC derivatives, including indices, forex, commodities, ETFs, and shares.

The platform offers millisecond execution, tight spreads, advanced risk mitigation, and multi-device compatibility, ensuring an intuitive trading experience tailored to every trader.

Trading involves risks. This article is for informational purposes only and not financial advice, an offer, or a solicitation.

Visit https://www.mitrade.com for more information.

 

Video series features CPPCC members’ insights on China’s next development stage

BEIJING, March 17, 2026 /PRNewswire/ — A special video series produced by the China Daily Opinion Channel during the annual two sessions brings together perspectives from five national political advisers on priorities for the 15th Five-Year Plan (2026-30) period.

Featuring interviews with five members of the 14th National Committee of the Chinese People’s Political Consultative Conference — Huang Qunhui, Jiang Ying, Dai Bin, Feng Li and Xu Jiuping — the series examines how China can advance high-quality growth, strengthen cultural vitality and cultivate future-ready talent.

Huang Qunhui, a researcher at the Institute of Economics, Chinese Academy of Social Sciences, emphasizes the role of developing “new quality productive forces” in supporting China’s modernization. He says China can draw on its institutional strengths, large market, industrial base and talent pool to upgrade traditional industries, expand domestic demand and proactively plan for emerging and future industries.

Jiang Ying, chair of Deloitte China, addresses the problem of excessive competition — often described as “involution”. She argues that the core issue is not competition itself, but that value is not fully reflected in pricing and market rules. During the next plan period, she calls for competition mechanisms guided by long-term value so that quality products, advanced technology and strong services can command fair prices. She also highlights sectors such as artificial intelligence and the low-altitude economy as key areas for breakthrough.

Dai Bin, president of the China Tourism Academy, discusses the recovery of inbound tourism and the popularity of “China Travel”. While facilitation has helped more visitors enter China, he notes that success depends on improving the experience after arrival. That includes developing new tourism resources, better mobilizing market players such as travel firms, and upgrading public services to encourage longer stays and deeper exploration.

Feng Li, president of the China National Opera & Dance Drama Theater, reflects on the arts as a source of cultural confidence. She stresses a people-centered approach and the importance of responding to the times. Citing the classic opera The White-Haired Girl, she says enduring works resonate because they tap universal emotions and renew themselves through sustained practice.

Xu Jiuping, a distinguished professor at Sichuan University, focuses on education in the AI era. While AI is reshaping industries and learning, he stresses that education must reinforce fundamental disciplines, language ability and critical thinking. Combining technological empowerment with humanistic knowledge, he says, is essential for nurturing innovative talent for the decade ahead.

https://www.chinadaily.com.cn/a/202603/12/WS69b79715a310d6866eb3e0ce.html

51WORLD Becomes NVIDIA’s Global L4 Simulation Partner to Accelerate Reasoning-Based Autonomous Driving Development!

HONG KONG, March 17, 2026 /PRNewswire/ — At the NVIDIA GTC Conference held on March 16, NVIDIA announced a deep integration between its Omniverse NuRec and 51WORLD’s SimOne. Leveraging neural rendering technology, this collaboration successfully solves the industry pain point where real-world collected scenario data is non-interactive. This breakthrough will accelerate the development of reasoning-based autonomous driving systems, such as VLA and World Models, empowering global L4 automotive partners.

It is reported that 51WORLD has achieved a 53.5% market share in China’s L3+ simulation sector. This partnership will further solidify 51WORLD’s core position in the global Physical AI arena.

51WORLD Becomes NVIDIA’s Global L4 Simulation Partner to Accelerate Reasoning-Based Autonomous Driving Development!

HONG KONG, March 17, 2026 /PRNewswire/ — At the NVIDIA GTC Conference held on March 16, NVIDIA announced a deep integration between its Omniverse NuRec and 51WORLD’s SimOne. Leveraging neural rendering technology, this collaboration successfully solves the industry pain point where real-world collected scenario data is non-interactive. This breakthrough will accelerate the development of reasoning-based autonomous driving systems, such as VLA and World Models, empowering global L4 automotive partners.

It is reported that 51WORLD has achieved a 53.5% market share in China’s L3+ simulation sector. This partnership will further solidify 51WORLD’s core position in the global Physical AI arena.

51WORLD Becomes NVIDIA’s Global L4 Simulation Partner to Accelerate Reasoning-Based Autonomous Driving Development!

SAN JOSE, Calif., March 17, 2026 /PRNewswire/ — At the NVIDIA GTC Conference held on March 16, NVIDIA announced a deep integration between its Omniverse NuRec and 51WORLD’s SimOne. Leveraging neural rendering technology, this collaboration successfully solves the industry pain point where real-world collected scenario data is non-interactive. This breakthrough will accelerate the development of reasoning-based autonomous driving systems, such as VLA and World Models, empowering global L4 automotive partners.

It is reported that 51WORLD has achieved a 53.5% market share in China’s L3+ simulation sector. This partnership will further solidify 51WORLD’s core position in the global Physical AI arena.

51WORLD Becomes NVIDIA’s Global L4 Simulation Partner to Accelerate Reasoning-Based Autonomous Driving Development!

SAN JOSE, Calif., March 17, 2026 /PRNewswire/ — At the NVIDIA GTC Conference held on March 16, NVIDIA announced a deep integration between its Omniverse NuRec and 51WORLD’s SimOne. Leveraging neural rendering technology, this collaboration successfully solves the industry pain point where real-world collected scenario data is non-interactive. This breakthrough will accelerate the development of reasoning-based autonomous driving systems, such as VLA and World Models, empowering global L4 automotive partners.

It is reported that 51WORLD has achieved a 53.5% market share in China’s L3+ simulation sector. This partnership will further solidify 51WORLD’s core position in the global Physical AI arena.